About Diagnostic Hybrids
Diagnostic Hybrids is a company based in Athens (United States) founded in 1983 was acquired by Quidel in January 2010. Diagnostic Hybrids has raised $10 million across 1 funding round from investors including Summit Partners, Kenson Ventures and QuidelOrtho. Diagnostic Hybrids offers products and services including QuickVue COVID-19 Test, Sofia Platform, Solana Molecular Testing Platform, and VITROS Systems. Diagnostic Hybrids operates in a competitive market with competitors including ArcherDX, Inscripta, GenScript, OncoDNA and Sino Biological, among others.
- Headquarter Athens, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Quidel Corporation
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$10 M (USD)
in 1 rounds
-
Latest Funding Round
$10 M (USD), Private Equity Round
Aug 11, 2004
-
Investors
Summit Partners
& 2 more
-
Employee Count
Not available
-
Acquired by
Quidel
(Jan 10, 2010)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Diagnostic Hybrids
Diagnostic Hybrids offers a comprehensive portfolio of products and services, including QuickVue COVID-19 Test, Sofia Platform, Solana Molecular Testing Platform, and VITROS Systems.
Fast test for detecting COVID-19 at home or point-of-care.
Benchtop system for rapid immunoassay and testing solutions.
Platform for efficient molecular testing in labs.
Systems for clinical chemistry and immunoassay processing.
Funding Insights of Diagnostic Hybrids
Diagnostic Hybrids has successfully raised a total of $10M through 1 strategic funding round. The most recent funding activity was a Private Equity Round of $10 million completed in August 2004. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Diagnostic Hybrids
Diagnostic Hybrids has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Summit Partners, Kenson Ventures and QuidelOrtho.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Summit Partners is recognized as a growth equity investment firm.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
QuidelOrtho is engaged in providing diagnostic testing solutions globally.
|
Locked | Locked | Locked |
Investor details for Diagnostic Hybrids
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Diagnostic Hybrids
Investment portfolio details for Diagnostic Hybrids
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Diagnostic Hybrids
Detailed financials for Diagnostic Hybrids
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Diagnostic Hybrids Comparisons
Peer comparison for Diagnostic Hybrids
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Diagnostic Hybrids
Diagnostic Hybrids operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ArcherDX, Inscripta, GenScript, OncoDNA and Sino Biological, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| Locked | Locked | Locked |
Speech recognition solutions are provided by Inscripta for healthcare professionals.
|
|
| Locked | Locked | Locked |
Reagents and instruments are provided for life sciences research.
|
|
| Locked | Locked | Locked |
Genomic and theranostic services for oncology precision medicine are delivered.
|
|
| Locked | Locked | Locked |
Reagents and kits are provided for clinical research applications.
|
|
| Locked | Locked | Locked |
Develops tools and products for research and clinical application
|
Detailed competitors of Diagnostic Hybrids
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Diagnostic Hybrids
Complete news archive for Diagnostic Hybrids
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Diagnostic Hybrids
Diagnostic Hybrids was founded in 1983 and raised its 1st funding round 21 years after it was founded.
Diagnostic Hybrids is headquartered in Athens, United States.
Diagnostic Hybrids is a funded company, having raised a total of $10M across 1 funding round to date.
Diagnostic Hybrids develops and manufactures cellular and molecular diagnostic kits for various applications in detecting a range of respiratory diseases, herpes infections, thyroid function, and other markers of diseases. The company offers a D3 FastPoint L-DFA influenza Ainfluenza B virus identification kit, which allows for the identification of influenza A virus and influenza B virus from a patients specimen in under 30 minutes. It also develops and commercializes genetically engineered cell-based detection products for the pharmaceutical and biotechnology industry with a focus on pharmacology assays and products that measure drug clearance and anti-viral interventions with drugs and vaccines.
Diagnostic Hybrids's top competitors include Sino Biological, OncoDNA and ArcherDX.
Diagnostic Hybrids offers QuickVue COVID-19 Test, Sofia Platform, Solana Molecular Testing Platform, and VITROS Systems.
Diagnostic Hybrids has 3 investors. Key investors include Summit Partners, Kenson Ventures, and QuidelOrtho.